Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irosanolin is a multi-component hematinic formulation developed by Kirovest, primarily indicated for the treatment and prevention of nutritional anemias. The product contains a synergistic blend of **iron**, **copper**, **folate** (Vitamin B9), **vitamin B12** (cobalamin), and **vitamin C** (ascorbic acid). Iron serves as the central component for hemoglobin production, while folate and vitamin B12 are essential for DNA synthesis and red blood cell maturation. Vitamin C is included to facilitate the gastrointestinal absorption of non-heme iron by maintaining it in the ferrous state, and copper acts as a cofactor for enzymes like ceruloplasmin that are involved in iron transport and metabolism. Irosanolin is typically administered as an oral tablet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Irosanolin.